Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy
Read MoreNews
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
August 17, 2020
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
August 4, 2020
Product Pipeline
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
